Overview

• The SURPASS-CVOT head-to-head trial showed Mounjaro cut major adverse cardiovascular events by 8% compared to Trulicity.
• Patients on Mounjaro experienced a 16% reduction in all-cause mortality relative to those taking Trulicity.
• The five-year study enrolled over 13,000 participants and recorded comparable gastrointestinal safety, with discontinuations at 13.3% for Mounjaro and 10.2% for Trulicity.
• Mounjaro outperformed Trulicity in renal function preservation and blood sugar control in secondary analyses.
• Eli Lilly plans to submit these trial results to the FDA this year to secure a 2026 cardiovascular risk-reduction label for Mounjaro.